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RNF219 attenuates global mRNA decay through
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The CCR4-NOT complex acts as a central player in the control of mRNA turnover and
mediates accelerated mRNA degradation upon HDAC inhibition. Here, we explored
acetylation-induced changes in the composition of the CCR4-NOT complex by purification of
the endogenously tagged scaffold subunit NOT1 and identified RNF219 as an acetylation-
regulated cofactor. We demonstrate that RNF219 is an active RING-type E3 ligase which
stably associates with CCR4-NOT via NOT9 through a short linear motif (SLiM) embedded
within the C-terminal low-complexity region of RNF219. By using a reconstituted six-subunit
human CCR4-NOT complex, we demonstrate that RNF219 inhibits deadenylation through the
direct interaction of the α-helical SLiM with the NOT9 module. Transcriptome-wide mRNA
half-life measurements reveal that RNF219 attenuates global mRNA turnover in cells, with
differential requirement of its RING domain. Our results establish RNF219 as an inhibitor of
CCR4-NOT-mediated deadenylation, whose loss upon HDAC inhibition contributes to
accelerated mRNA turnover.
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Transcription and mRNA turnover jointly determine theabundance of any given mRNA in the cell, thus enablingadaptation of mRNA expression profiles with current cel-
lular needs. Regulation of mRNA stability represents a key step in
the control of post-transcriptional gene expression and shapes the
kinetics of critical cellular processes such as cell proliferation,
differentiation, immunity, and development1–7. Moreover, per-
turbation of mRNA turnover is associated with a variety of
pathologies including oncogenesis, inflammation, and
neurodegeneration8–11. Hence, uncovering molecular pathways
governing both global and transcript-specific mRNA stability is
essential to understanding the dynamics of gene expression.
The poly(A) tail at the 3′end of mRNAs, together with the 5′-
m7G-cap structure at the 5′end, acts as an integral stability
determinant and facilitates cap-dependent translation. In eukar-
yotes, deadenylation-dependent mRNA turnover is the primary
pathway for the degradation of most mRNAs12–15, whereby
deadenylation represents the first and rate-limiting step in this
process16. The multisubunit carbon catabolite repression 4
(CCR4)-negative on TATA-less (NOT) complex functions as the
principal deadenylase responsible for processive poly(A) tail
shortening in eukaryotic cells and is essential for normal rates of
mRNA turnover17–21.
The evolutionarily conserved CCR4-NOT complex contains
two 3′−5′ exoribonucleases, the EEP-type deadenylase CCR4 and
the DEDD-type deadenylase CCR4-associated factor 1 (CAF1).
The concerted action of both 3′−5′ exoribonucleases contributes
to the shortening of poly(A) tails in yeast and human cells, albeit
with different specificities towards poly(A)-binding protein
(PABP)-protected segments22,23. In contrast to the yeast CCR4-
NOT complex, the composition of the metazoan complex is
heterogenous since there are two paralogs each of CAF1 (CAF1a/
CNOT7, CAF1b/CNOT8) and CCR4 (CCR4a/CNOT6, CCR4b/
CNOT6L), whose incorporation into the complex is mutually
exclusive24. The complex is organized around NOT1, which
serves as a large scaffold protein that provides a binding platform
for the catalytic deadenylase module and three non-catalytic
modules25. CCR4 stably associates with the complex via CAF1,
which docks onto the central, α-helical MIF4G domain of NOT1,
together forming the catalytic module26,27. The C-terminal end of
NOT1 interacts with the NOT2 and NOT3 subunits to form the
so called NOT module28,29. The N-terminal portion of
NOT1 stably binds the metazoan-specific NOT10 and
NOT11 subunits30,31. The third non-catalytic module assembles
on a central region of NOT1 close to the catalytic module, and
includes the NOT9 subunit, the human homolog of yeast
Caf4032,33. The RING-type E3 ligase NOT4 interacts via NOT9/
Caf40 with the CCR4-NOT complex, though it is stably asso-
ciated with the complex only in yeast24,34–38. In metazoans,
NOT9 serves as an adaptor for multiple RNA-binding proteins
(RBPs) such as Tristetraprolin (TTP), GW182/TNRC6, Bag-of-
marbles (Bam), and Roquin which induce selective mRNA
degradation32,33,39–41.
Aside from recruitment of specific target mRNAs to the CCR4-
NOT complex via RBPs recognizing 3′UTR elements2,42–48 the
CCR4-NOT complex also promotes the deadenylation of bulk
mRNA through a generic pathway that involves PABPC1 and
members of the BTG/TOB family49–51. Moreover, CCR4-NOT-
mediated deadenylation is regulated by post-translational mod-
ifications (PTMs) such as ubiquitination and acetylation of
CAF152,53 as well as phosphorylation of TOB254. However, little
is known about signaling-dependent alterations in the composi-
tion of the CCR4-NOT complex and how these affect its enzy-
matic activity. Based on our previous observation that HDAC
inhibition dramatically accelerates global poly(A) RNA turnover
via CCR4-NOT-mediated deadenylation53, we set out to explore
whether pharmacological HDAC inhibition alters the composi-
tion of the CCR4-NOT complex.
Results
RNF219 is an acetylation-regulated subunit of the CCR4-NOT
complex. We previously discovered that protein acetylation has a
profound impact on global mRNA turnover53, whereby inhibition
of HDAC1 and HDAC2 induces widespread degradation of bulk
poly(A) RNA in mammalian and Drosophila melanogaster (Dm)
cells. Since acetylation-induced mRNA turnover depends on
deadenylation53, we asked whether there may be acetylation-
regulated changes in the protein interactome of the CCR4-NOT
complex. So far, the composition of the mammalian CCR4-NOT
complex was assessed by affinity purification-mass spectrometry
(MS) using ectopically expressed subunits24,31,55. Since we wan-
ted to explore physiological changes in the composition of the
CCR4-NOT complex, we employed a genome editing approach to
purify the endogenous complex from HeLa cells. To this end, the
start codon of the scaffold subunit NOT1, located in exon 2, was
targeted by CRISPR/Cas9-mediated cleavage, followed by inser-
tion of an N-terminal 3xFLAG-2xStrep (FST) tag via homology-
directed repair (Fig. 1a). Individual HeLa clones were tested for
FST-NOT1 expression, and Sanger sequencing of the targeted
locus in clone #47, which was used for all subsequent experi-
ments, confirmed in-frame integration of the FST sequence
downstream of the start codon in one CNOT1 allele (Supple-
mentary Fig. 1). FST-NOT1 co-sediments with other CCR4-NOT
subunits in a linear glycerol gradient (Supplementary Fig. 2a),
indicative of proper incorporation and assembly of the endo-
genous complex. Further characterization of clone #47 revealed
that the expression level of NOT1 is similar to that of parental
HeLa cells (Supplementary Fig. 2b). Moreover, treatment of clone
#47 with the class I-specific HDAC inhibitor Romidepsin
(RMD)56 led to a more than two-fold acceleration of poly(A)
RNA turnover (Supplementary Fig. 2c; half-life of 7.6 ± 1.1 vs.
3.6 ± 0.5 h), similar to what was observed in parental HeLa cells53.
We then purified the complex by FLAG-based immunopreci-
pitation (IP) of FST-NOT1, and analyzed its composition by
protein MS. As a negative control, the same IP was conducted in
parental HeLa cells. Thereby we observed the specific enrichment
of all canonical subunits of the CCR4-NOT complex in the FST-
NOT1 purification, while none of these proteins were detected in
the control IP (Fig. 1b, blue dots, Supplementary Data 1). Our
purification strategy further recovered the mammalian-specific
component TNKS1BP1 (also known as TAB182), which was
identified as a stable interactor of the CCR4-NOT complex in
previous studies24,57,58. Six additional proteins were strongly
enriched in our FST-NOT1 purification (Fig. 1b, red dots): four
and a half LIM domains protein 2 (FHL2), ring finger protein 219
(RNF219), two actin-associated proteins CAPZA1 and CAPZB,
ribonucleoprotein PTB-binding 1 (RAVER1), as well as riboso-
mal protein L7 (RPL7). Purification of FST-NOT1 followed by
western blot analysis confirmed that RNF219, FHL2 as well as
CAPZA1 and CAPZB associate with the CCR4-NOT complex,
whereas RAVER1 and RPL7 could not be detected in the IP
(Fig. 1c). Importantly, the co-purification of both RNF219 and
FHL2 with the CCR4-NOT complex was not affected by RNase
treatment (Supplementary Fig. 2d, e), indicating that their
association is based on protein–protein interactions. Moreover,
well-known interactors of the CCR4-NOT complex such as
members of the BTG/TOB family59,60, the facultative cofactor
NOT424,37 or other decay-promoting RBPs were not enriched by
FST-NOT1 purification (Fig. 1b), suggesting that our isolation
strategy retained only factors that are stably associated with the
CCR4-NOT complex.
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To investigate the effect of pharmacological HDAC inhibition
on the composition of the CCR4-NOT complex, we made use of
quantitative proteomics by stable isotope labeling with amino
acids in cell culture (SILAC; Supplementary Fig. 2f). Following
differential isotope labeling of FST-NOT1 HeLa cells treated with
RMD or solvent (DMSO), equal quantities of heavy- and light-
labeled protein extract were combined, subjected to FST-NOT1
purification, and analyzed by protein MS (Supplementary Data 1).
The same approach was also used to assess background binding
in parental HeLa cells. Whereas the association of all canonical
subunits with FST-NOT1 was barely affected by RMD treatment,
the amount of co-precipitated RNF219 was reduced by more than
two-fold (Fig. 1d), indicating that this factor may be regulated by
acetylation. Consistent with the SILAC-based quantification, the
amount of co-precipitated RNF219 was reduced by approxi-
mately four-fold upon RMD treatment when assessed by western
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blot analysis, whereas the association of FHL2 as well as CAPZA1
and CAPZB remained largely unaffected (Fig. 1c, e).
We then monitored association of RNF219 and FHL2 with the
CCR4-NOT complex by glycerol gradient centrifugation and
found that both proteins co-sediment together with core
components of the complex in fractions 8–12 (Supplementary
Fig. 3a, b). Moreover, both proteins shifted to lighter fractions
upon siRNA-mediated knock-down (KD) of the scaffold
component NOT1 (Supplementary Fig. 3a, b). Co-IP of
RNF219 and FHL2 with FST-NOT1 was also observed when
isolated from heavy fractions of a glycerol gradient (Supplemen-
tary Fig. 3c), providing further evidence that both factors are
stably associated with the core CCR4-NOT complex.
To better understand the reason for reduced association of
RNF219 with the CCR4-NOT complex, we measured changes in
RNF219 pre-mRNA, mRNA, and protein expression upon HDAC
inhibition by RMD and two pan-HDAC inhibitors, Trichostatin
A (TSA) and suberoylanilide hydroxamic acid (SAHA). This
analysis revealed a significant reduction of RNF219 pre-mRNA,
mRNA, and protein expression after 16 h of inhibition (Supple-
mentary Fig. 4a, b). The observation that all three HDAC
inhibitors decreased RNF219 pre-mRNA levels (Supplementary
Fig. 4a, right panel) prompted us to further investigate the
involvement of HDACs in RNF219 transcription. Analysis of
ChIP-Seq data derived from primary human CD4+ T-cells61
revealed HDAC1 and RNA polymerase II (PolII) occupancy
across the first exon of RNF219 (Supplementary Fig. 4c),
suggesting a function of HDAC1 in RNF219 transcription. We
therefore tested siRNA-mediated knock-down of HDAC1 and
found this to significantly reduce RNF219 pre-mRNA expression
(Supplementary Fig. 4d, right panel) and cause a moderate
decrease in RNF219 mRNA and protein levels (Supplementary
Fig. 4d, e). Hence, HDAC1 inhibition compromises RNF219
expression due to transcriptional downregulation. Although the
inhibition of class-I HDACs accelerates the degradation of
poly(A)-containing mRNAs53, RNF219 mRNA stability was
barely affected by RMD treatment (Supplementary Fig. 4f),
excluding the possibility that reduced RNF219 expression is
linked to changes in its mRNA half-life. In conclusion,
transcriptional regulation represents the primary reason for the
RMD-mediated decrease in RNF219 expression, which ultimately
results in the depletion of RNF219 from the CCR4-NOT
complex.
Taken together, purification of the endogenous complex
identified RNF219, FHL2 as well as CAPZA1 and CAPZB as
stable interactors of the CCR4-NOT deadenylase. While the
association of FHL2, CAPZA1 and CAPZB is acetylation-
independent, RNF219 dissociates from the CCR4-NOT complex
as a consequence of its reduced expression upon RMD-mediated
hyperacetylation.
RNF219 binds to the NOT9 module via a short linear motif. So
far, RNF219 was characterized as a ubiquitin ligase that promotes
replication origin firing via ubiquitination of the origin recogni-
tion complex62. Moreover, an interactome study indicated a
connection between RNF219 and the CCR4-NOT complex,
whereby RNF219 was placed in close proximity to NOT9 based
on biotinylation experiments55. Guénolé et al. recently reported
that residues 540–549 in the C-terminus of RNF219 mediate
binding to the CCR4-NOT complex (Fig. 2a)63. Interestingly,
several RBPs were previously shown to associate with the CCR4-
NOT complex through direct binding to the NOT9/Caf40 subunit
via short linear motifs (SLiMs), also termed Caf40-binding motifs,
which are embedded within low-complexity regions37,40,41.
We first investigated whether RNF219 may associate with the
CCR4-NOT complex via the NOT9 module. Strikingly, a partial
KD of NOT9 was sufficient to prevent the co-precipitation of
RNF219, but not FHL2, with FST-NOT1 in HeLa cells (Fig. 2b),
indicating that NOT9 is essential for recruitment of RNF219 to
the CCR4-NOT complex.
To test whether this interaction is direct, we produced a
recombinant fragment comprising the entire C-terminal low-
complexity region of RNF219 (residues 434-726), termed
RNF219-C (Fig. 2a). The fragment was tagged at the
N-terminus with maltose-binding protein (MBP) and immobi-
lized on StrepTactin beads via a C-terminal StrepII tag. RNF219-
C was then incubated with all four functional CCR4-NOT
subcomplexes reconstituted from purified recombinant
proteins25, and found to specifically bind to the NOT9 module,
but not the NOT10/11, the catalytic NOT6/7, or the NOT module
(Fig. 2c).
Next, we sought to confirm that residues 540-549 represent a
SLiM through which RNF219 associates with the CCR4-NOT
complex and expressed RNF219 fused N-terminally to a 3xFLAG-
SBP (3xFS) tag in HeLa cells. Whereas wild-type (WT) RNF219
efficiently co-immunoprecipitated NOT9 as well as NOT2, the
ΔSLiM mutant failed to do so (Fig. 2d). This result was
corroborated by a reciprocal pull-down where HA-tagged
NOT9 was found to co-immunoprecipitate WT RNF219 but
not the ΔSLiM mutant (Supplementary Fig. 5). Furthermore, we
observed that RNF219-ΔSLiM co-sediments in lighter fractions of
a linear glycerol gradient as compared to its WT counterpart
(Fig. 2e, quantification on the right side). In fact, RNF219-ΔSLiM
showed only a small shift by one fraction in the glycerol gradient,
indicating that apart from the C-terminal SLiM, RNF219 might
establish additional, low-affinity interactions with the CCR4-
NOT complex.
Taken together, our interaction analyses provide compelling
evidence for a stable and specific interaction between RNF219
and the NOT9 module of the CCR4-NOT complex, mediated by
a SLiM embedded within the low-complexity region of RNF219.
Fig. 1 Purification of the endogenously tagged CCR4-NOT complex. a Schematic illustration of the CRISPR/Cas9 strategy for N-terminal tagging of
endogenous CNOT1 in HeLa cells. Integration of the 3xFLAG-2xStrep (FST) sequence downstream of the ATG start codon was achieved by two guide RNAs
introducing double-strand DNA breaks (DSBs) and homology-directed repair using a donor plasmid; HA, homology arm; PAM, protospacer adjacent motif.
b Scatter plot depicts proteins identified by mass spectrometry following FLAG IP from FST-NOT1 or parental HeLa cells as negative control. Canonical
subunits of the CCR4-NOT complex are shown in blue, candidate interactors in red; values represent the means of log2-transformed LFQ intensities of
n= 4 independent biological replicates; LFQ, label-free quantification. c Validation of candidate CCR4-NOT interactors by western blot analysis using
antibodies as indicated. The endogenous CCR4-NOT complex was purified by FLAG IP from FST-NOT1 or parental HeLa cells treated with 20 nM RMD or
an equal volume of DMSO for 16 h. d Dot plot depicts the SILAC ratio of canonical CCR4-NOT subunits and candidate interactors determined by mass
spectrometry. Samples were processed as illustrated in Supplementary Fig. 2f; values are presented as mean ± SD (n≥ 2) including two label-swap
replications (CNOT2, n= 4, p= 0.0147; CNOT3, n= 4, p= 0.018; CNOT6L, n= 4, p= 0.0133; CNOT8, n= 4, p= 0.0084; CNOT11, n= 4, p= 0.0173;
RNF219, n= 3, p= 0.0049). e Dot plot shows the quantification of western blots as in (c). Values are presented as mean ± SD (n= 3; RNF219, p= 0.0021;
CAPZB, p= 0.0326). Statistical significance in panel (d) and (e) was determined by using a two-sided, one-sample t test (*p < 0.05; **p < 0.01). Source
data for panels (b–e) are provided as a Source Data file.
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RNF219 is a CCR4-NOT-associated active ubiquitin ligase.
RNF219 harbors an N-terminal RING-type E3 ligase domain,
which displays high amino acid sequence conservation among
vertebrates (Supplementary Fig. 6a) and conforms to the con-
sensus sequence of other RING-type E3 ligases (Fig. 3a)64.
Indeed, two recent studies independently confirmed that RNF219
is an active E3 ubiquitin ligase62,63.
To determine if RNF219 acts as an E3 ubiquitin ligase within
the CCR4-NOT complex, we made use of the observation that E3
ligases frequently undergo autoubiquitination65. We assessed the
protein half-life of RNF219 following arrest of protein synthesis
by treatment with cycloheximide (CHX) and found that RNF219-
WT is rapidly degraded with a half-life of 2.5 h (Fig. 3b). In
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Fig. 2 RNF219 associates with the CCR4-NOT complex via NOT9. a Schematic illustration of the domain architecture of RNF219; RING, really interesting
new gene; SLiM, short linear motif. RNF219-C (amino acid residues 434–726) and RNF219-ΔSLiM are shown below. b Co-precipitation of RNF219 was
examined by FLAG IP of the endogenous CCR4-NOT complex from FST-NOT1 HeLa cells following transfection with either control or NOT9-targeting
siRNAs for 48 h. Proteins were analyzed by western blotting with antibodies as indicated; the asterisks denote non-specific bands. c Coomassie-stained
polyacrylamide gel of in vitro pull-down assays with recombinant RNF219-C fused to maltose-binding protein (MBP) and a StrepII (Strep) affinity tag upon
incubation with four different CCR4-NOT modules as indicated. d Co-IP of endogenous NOT2 and NOT9 with RNF219 using HeLa cells stably expressing
3xFLAG-SBP (3xFS)-RNF219-WT or 3xFS-RNF219-ΔSLiM. Precipitated proteins were detected by western blot analysis using antibodies as indicated. e Co-
sedimentation analysis of CCR4-NOT subunits by 10–30% linear glycerol gradient fractionation and western blotting from HeLa cells stably expressing
3xFS-RNF219-WT or 3xFS-RNF219-ΔSLiM. The core CCR4-NOT complex elutes in fractions 7–14. Data from one representative experiment are shown
(left panel), and the relative distribution of RNF219 and NOT7 along the gradient was quantified (right panel); values are presented as mean ± SD (WT
n= 3; ΔSLiM n= 4; fraction 8, p= 0.0313; fraction 9, p= 0.0154; fraction 14, p= 0.0106). The asterisks denote non-specific bands. p values were
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Fig. 3 RNF219 is a CCR4-NOT complex-associated RING-type E3 ligase. a Amino acid sequence alignment of the RNF219 RING domain with other RING-
type E3 ligases. Cysteine and histidine residues involved in zinc atom coordination are highlighted in red. Cysteines at position 18 and 21 were mutated to
serine in RNF219-RINGmut, shown in green. b Protein stability of 3xFS-RNF219-WT and 3xFS-RNF219-RINGmut was assessed in transiently transfected
HeLa cells following translation shut-off with 100 µM cycloheximide (CHX). Proteins were isolated at regular time intervals and detected by western blot
analysis using α-FLAG and α-tubulin antibodies. 3xFS-RNF219-WT and -RINGmut protein half-lives are presented as mean ± SD (n= 3). c In vitro
ubiquitination assay showing autoubiquitination of RNF219 within the endogenous CCR4-NOT complex. Native CCR4-NOT complexes were purified from
HeLa cells expressing FST-NOT1, eluted with 3xFLAG peptide, and incubated with recombinant E1 enzyme (UBA1), E2 enzyme (UbcH5b) and ubiquitin in
the absence or presence of 5 mM ATP. Reaction products were detected by western blot analysis as indicated. d In vitro ubiquitination assay showing
autoubiquitination of RNF219 in the presence and absence of the CCR4-NOT complex. CCR4-NOT complexes were purified from CRISPR control or NOT9
KO HeLa cells stably expressing 3xFS-RNF219 by FLAG IP and used for in vitro ubiquitination assays as described in (c). The asterisk denotes a non-specific
band. e Total protein lysates derived from two control and two RNF219 KO HeLa clones were analyzed by western blotting using antibodies as indicated.
Source data for panels (b–e) are provided as a Source Data file.
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domain (RNF219-RINGmut; Fig. 3a) lead to an increase in
protein stability with a half-life exceeding 12 h (Fig. 3b),
suggesting that RNF219 undergoes rapid turnover due to
autoubiquitination.
To assess RNF219 E3 ligase activity more directly, we
performed in vitro ubiquitination assays with 3xFS-tagged
RNF219 immuno-purified from HEK293 cells. 3xFS-RNF219
was then incubated with recombinant E1 enzyme (UBA1),
different E2 enzymes (UbcH5b/c, UbcH10, Cdc34) and ubiquitin
in the absence or presence of ATP (Supplementary Fig. 6b).
During the reaction, RNF219-WT was extended to a range of
high molecular weight species, indicative of E3 ligase autoubi-
quitination, whereas RNF219-RINGmut did not show this
activity (Supplementary Fig. 6b). Moreover, these in vitro
ubiquitination assays revealed that RNF219 cooperates with the
promiscuous ubiquitin-conjugating enzymes UbcH5b and
UbcH5c66, but not with the cell cycle-related UbcH10 or Cdc34
enzymes67.
Because of its stable association with the CCR4-NOT complex,
we then asked if RNF219 retains E3 ligase activity when bound to
the deadenylase complex. In vitro RNF219 autoubiquitination
assays were carried out with native CCR4-NOT complexes
isolated from FST-NOT1 HeLa cells. Indeed, all the CCR4-NOT-
bound RNF219 protein showed extensive autoubiquitination as
evident from a drastic shift in molecular weight (Fig. 3c). To
assess if the association of RNF219 with the CCR4-NOT complex
affects its E3 ligase activity, we generated NOT9 knock-out (KO)
HeLa cells stably expressing 3xFS-RNF219 by CRISPR/Cas9-
mediated genome editing (Supplementary Fig. 7). Characteriza-
tion of a selected NOT9 KO clone confirmed that it expresses
equal levels of 3xFS-RNF219 as compared to a CRISPR control
clone, and lacks NOT9 expression (Fig. 3d, input) due to
deletions downstream of the guide RNA target sequence in exon 2
(Supplementary Fig. 8a, b). As expected from our in vitro binding
results (Fig. 2c), loss of NOT9 expression precluded co-
purification of the CCR4-NOT complex by 3xFS-RNF219 IP
(Fig. 3d). Interestingly, in vitro ubiquitination assays performed
with 3xFS-RNF219 IP eluates derived from control or NOT9 KO
cells did not show differences in RNF219 autoubiquitination.
Hence, RNF219 is an active CCR4-NOT-associated RING-type
E3 ligase, whose activity is not affected by its binding to the
CCR4-NOT complex.
Given its capacity to promote its own degradation (Fig. 3b) and
act as an efficient ubiquitin E3 ligase within the CCR4-NOT
complex (Fig. 3c, d), we asked if RNF219-mediated ubiquitination
may affect the abundance of CCR4-NOT subunits or alter the
composition of the complex. To this end, we generated RNF219
KO HeLa cells by CRISPR/Cas9-mediated genome editing
(Supplementary Fig. 9a). Characterization of two selected
RNF219 KO clones confirmed that they fail to express RNF219
(Fig. 3e) due to a deletion (clone #16) or insertion (clone #30) in
the vicinity of the ATG start codon (Supplementary Fig. 9b).
However, the abundance of core CCR4-NOT subunits (NOT1-3,
NOT6-7, NOT9-10) remained unaffected in both RNF219 KO
clones (Fig. 3e). Moreover, the loss of RNF219 did not lead to
detectable differences in the sedimentation of core CCR4-NOT
subunits (NOT1-3, NOT6-7) in a linear glycerol gradient
(Supplementary Fig. 10). These results indicate that RNF219-
mediated ubiquitination does not influence the composition of
the CCR4-NOT complex or promote proteolytic degradation of
core subunits other than RNF219 itself.
RNF219 inhibits CCR4-NOT-mediated deadenylation. To
delineate the function of RNF219 within the CCR4-NOT com-
plex, we first analyzed its impact on CCR4-NOT-mediated
deadenylation in vitro. Previously, we showed that the human six-
subunit CCR4-NOTMINI complex (Fig. 4a), which contains the
full-length exoribonucleases NOT6 (CCR4a) and NOT7 (CAF1a),
the C-terminal half of NOT1 (residues 1093-2376), NOT9 (resi-
dues 19-285), as well as the minimal constructs of NOT2 (resi-
dues 344-540) and NOT3 (residues 607-753), exhibits almost the
same deadenylation activity as the full complex25. Since the
C-terminal half of RNF219 efficiently binds to the NOT9 module
(Fig. 2c), we assessed the impact of RNF219-C on the activity of
the reconstituted CCR4-NOTMINI complex by monitoring the
deadenylation of a 5′-fluorescein-labeled 7-mer RNA substrate
containing a poly(A) tail of twenty adenosines. Addition of an
almost saturating concentration of MBP-tagged RNF219-C,
equivalent to a 45-fold molar excess, led to pronounced inhibition
of deadenylation (Fig. 4b, compare MBP-Strep alone to MBP-
RNF219-C). The extent of inhibition was similar to that observed
for the Caf40-binding motif of the Dm Bam protein (Fig. 4b), a
known inhibitor of CCR4-NOT-mediated deadenylation25. To
quantify the kinetics of in vitro deadenylation68, line scans were
used to identify the most abundant deadenylation intermediates
(Supplementary Fig. 11a), from which an apparent deadenylation
rate was calculated (Fig. 4c). This analysis revealed that RNF219-
C elicited a three- to four-fold reduction in the apparent dead-
enylation rate of the CCR4-NOTMINI complex. Moreover,
RNF219-mediated inhibition of deadenylation is a consequence
of its direct association with the NOT9 module since no change in
the apparent deadenylation rate was detected in the presence of
the nuclease module alone (Fig. 4d, e). A titration experiment
revealed that CCR4-NOTMINI was progressively inhibited by
increasing concentrations of RNF219-C with a 50-fold molar
excess (2.5 µM) being sufficient to almost completely inhibit
deadenylation (Fig. 4f). RNF219 acts as an efficient antagonist of
CCR4-NOTMINI-mediated deadenylation since inhibition was
already apparent at an equimolar concentration of substrate,
CCR4-NOTMINI and RNF219-C (0.05 µM). Importantly,
RNF219-C did not bind to the RNA substrate at any of the tested
concentrations (Supplementary Fig. 11b, c), excluding the possi-
bility that the observed inhibition of deadenylation is due to RNA
sequestration. Hence, RNF219 has the capacity to directly inhibit
CCR4-NOT-mediated deadenylation in vitro. Given that RNF219
interacts with the CCR4-NOT complex through the NOT9
module (Fig. 2c), this result is consistent with our previous
finding that NOT9 serves as the dominant RNA-binding site of
the CCR4-NOT complex in vitro25.
The SLiM of RNF219 folds into an α-helix on the RNA-binding
surface of NOT9. To characterize the interaction of the RNF219
SLiM with NOT9 on a structural level, we employed the
AlphaFold2 structure prediction tool69,70. A single polypeptide
comprising the NOT9 sequence fused C-terminally to the
RNF219 disordered C-terminal region via a polyglycine linker
was provided to the prediction analysis pipeline in absence of any
imposed constraints, and five models were generated (Supple-
mentary Fig. 12a). Remarkably, in each of the five models, the
RNF219 SLiM was predicted to fold into an amphipathic α-helix
extending through residues S525–S548 and is positioned across
the concave surface of NOT9 (Fig. 5a, Supplementary Fig. 12a),
which consists of α-helical armadillo repeats32,33,71. The SLiM
binds into the positively charged pocket of NOT9 (Fig. 5b) that
was proposed as a nucleic acid-binding groove71, and thus
occupies the same binding surface as the previously described
SLiMs of Dm Roquin40 and Bam41 (Supplementary Fig. 12b).
We then examined possible contacts between the RNF219
SLiM and the positively charged pocket in NOT9 and noted three
side chains of the hydrophobic residues L541, M544, and M545 in
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Fig. 4 RNF219 inhibits CCR4-NOT-mediated deadenylation in vitro. a Scheme representing the architecture of the recombinant CCR4-NOTMINI complex;
MIF4G, middle domain of eukaryotic initiation factor 4G; CC, coiled-coil. b In vitro deadenylation assay with 50 nM of a 7-mer-A20 RNA substrate, 50 nM
CCR4-NOTMINI complex, and 2250 nM of either MBP-Strep, Dm MBP-Bam Caf40-binding motif (residues 13-36) or MBP-RNF219-C. Reactions were
stopped at the indicated time points and analyzed by electrophoresis using a 20% denaturing polyacrylamide gel; M, RNA size marker; C, RNA alone
control. c Quantification of the change in poly(A) tail length in (b) by plotting the most abundant tail length at each time point. Linear regression was used
to determine the apparent deadenylation rate (As/min); values are presented as mean ± SE (n= 3). d In vitro deadenylation assay with 50 nM of a 7-mer-
A20 RNA substrate, 50 nM CCR4-NOTMINI complex (left) or 250 nM NOT6:NOT7 exonuclease heterodimer (right), and 2250 nM of MBP-Strep or MBP-
RNF219-C. Reactions were stopped at the indicated time points and analyzed as described in (b). e Quantification of the change in poly(A) tail length in (d)
by plotting the most abundant tail length at each time point; values are presented as mean ± SE (n= 3). f In vitro deadenylation assay with 50 nM of the 7-
mer-A20 RNA and 50 nM of the CCR4-NOTMINI complex. MBP-Strep alone or MBP-RNF219-C were titrated into the reaction (0.05–5.0 µM). Reactions
were stopped after 32min. Source data for panels (b–f) are provided as a Source Data file.
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RNF219 that are likely to engage the NOT9 pocket. To validate
the predicted interface, we substituted the three residues with
glutamic acid, and tested the SLiM-3E mutant in pull-down
assays. Strikingly, the 3E substitution abolished binding of a
minimal, MBP-tagged RNF219 fragment (residues 434-600) with
the NOT9 module to the same extent as the deletion of the entire
SLiM (Fig. 6a, b). To further validate the predicted RNF219-
NOT9 interface, we compared the inhibitory profiles of the
RNF219 434-600 region with the ΔSLiM and SLiM-3E counter-
parts. This revealed that the 3E substitution eliminated the ability
of the RNF219 434-600 region to inhibit CCR4-NOT-mediated
deadenylation in vitro to the same extent as deletion of the entire
SLiM (Fig. 6c, d). Given that the SLiM residues predicted to
contact NOT9 are fully conserved among vertebrates (Supple-
mentary Fig. 12c), this motif may represent an evolutionarily
conserved mode of NOT9 binding, which could not be previously
identified by sequence analysis alone41.
RNF219 is a negative regulator of global mRNA degradation.
We then set out to investigate the role of RNF219 in cellular
mRNA turnover using parental and RNF219 KO HeLa cells. In
addition, we established rescue cell lines that stably express 3xFS-
RNF219-WT or the catalytically inactive RING finger mutant
RNF219-RINGmut in the KO background (Fig. 7a). The level of
3xFS-RNF219-WT was approximately nine-fold higher than that
of endogenous RNF219, while the level of 3xFS-RNF219-
RINGmut was approximately 14-fold higher (Fig. 7a), con-
sistent with its enhanced stability and lack of autoubiquitination
activity (Fig. 3b, Supplementary Fig. 6b). Importantly, both WT
and RINGmut 3xFS-RNF219 were found to co-sediment with
core CCR4-NOT subunits upon glycerol gradient centrifugation
(Supplementary Fig. 13a, b), demonstrating that the ectopically
expressed proteins are properly incorporated into the endogenous
CCR4-NOT complex.
To determine transcriptome-wide mRNA half-lives by RNA-
Seq, total RNA was extracted from the four cell lines at regular
time intervals after transcriptional shut-off with actinomycin D
(actD). Following depletion of ribosomal RNA and preparation of
libraries for RNA-Seq, mRNA half-lives were calculated based on
normalizing read counts to external RNA spike-in controls. By
assuming first-order decay kinetics and requesting a coefficient of
determination (R2) > 0.5 for the analysis of log-transformed read
counts by linear regression, reliable half-lives could be calculated
for 1909 mRNAs from two independent biological replicates
(Supplementary Data 2). The result of this analysis showed that
the loss of RNF219 led to a global reduction in mRNA half-lives,
with most mRNAs below the diagonal (Fig. 7b). This corresponds
to a reduction of the median mRNA half-life from 4.9 h in
parental HeLa cells to 4.0 h in RNF219 KO cells. Interestingly,
this global effect could be rescued by ectopic expression of both
RNF219-WT and RNF219-RINGmut (Fig. 7c, Supplementary
Fig. 14a, b), indicating that RNF219 acts as a negative regulator of
global mRNA turnover in cells independently of its E3 ligase
activity. These results are in line with our observation that
RNF219-C, which lacks the N-terminal RING domain, exerts an
inhibitory effect on the deadenylation activity of the CCR4-NOT
complex in vitro (Fig. 4).
When the effect of RNF219 depletion was assessed for mRNAs
grouped according to their half-lives, the destabilizing effect was
observed for all categories (Fig. 7d), albeit long-lived mRNAs (t1/
2 > 12 h) displayed a stronger dependency on RNF219 expression.
Notably, RNF219-WT restored the stability of all mRNAs,
whereas RNF219-RINGmut was able to restore the stability of
short-lived mRNAs (t1/2 ≤ 6 h), but not of the more long-lived
mRNAs (t1/2 > 9 h). Since the RNF219 rescue pattern of short-
lived mRNAs resembled that of global mRNA (Fig. 7c), we
focused on more labile subgroups of mRNAs that are recruited to
the CCR4-NOT complex by different RBPs. On the one hand,
mRNAs associated with the m6A-binding protein YTHDF272
(Supplementary Fig. 14c, Supplementary Data 3), the AU-rich
element-binding protein TTP73 (Supplementary Fig. 14d, Sup-
plementary Data 3) or the stem-loop-binding protein Roquin74
(Supplementary Fig. 14e, Supplementary Data 3) were destabi-
lized in RNF219 KO cells to a similar degree as bulk mRNA
(Fig. 7c). On the other hand, mRNAs transcribed from immediate
early genes (IEGs)75, which are more labile than the other
subgroups, showed stronger destabilization upon RNF219 KO
(Fig. 7e, Supplementary Data 3). Interestingly, the half-lives of
these mRNAs were substantially increased in cells overexpressing
RNF219-RINGmut (Fig. 7e), an observation that we verified by
measuring the half-lives of three IEG mRNAs, KLF4, MYC and
RHOB, by qRT-PCR (Fig. 7f and Supplementary Fig. 14f). Taken
together, these analyses led us to conclude that RNF219 acts as a
general inhibitor of the CCR4-NOT deadenylase complex that
attenuates the degradation of mRNAs transcriptome-wide, with a
pronounced effect on IEG mRNAs.
Next, we asked whether RNF219 participates in regulating
acetylation-induced mRNA turnover53. To this end, we compared
parental HeLa cells with our stable HeLa cell line expressing
elevated levels of RNF219-RINGmut (Fig. 7g). GAPDH and NCL,
two very stable mRNAs under control conditions, showed











































Fig. 5 Structure prediction of the RNF219 SLiM in complex with NOT9. a AlphaFold2-predicted structure of the RNF219 SLiM (orange cartoon) bound to
NOT9 (gray) shown in two orientations. NOT9 helices are depicted as tubes and are numbered in black. The Dm Bam SLiM (cyan cartoon) is superposed
on RNF219. b Electrostatic surface potential (with red representing negatively charged patches and blue positive ones) plotted onto the molecular surface
of NOT9. The predicted bound RNF219 SLiM is shown as a cartoon (orange) with side chains of residues in stick representation. Visible residues are
indicated with labels and residues substituted for glutamic acid are indicated in boxes.
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when parental HeLa cells were treated with the HDAC inhibitor
RMD (Fig. 7h), akin to the destabilization observed by KD of
HDAC1 and HDAC253. In the RNF219-RINGmut expressing
cells, however, GAPDH and NCL mRNA were less labile upon
treatment with RMD (Fig. 7h and Supplementary Fig. 14g). Given
that RMD treatment causes a pronounced drop in RNF219
expression (Fig. 1 and Supplementary Fig. 4a, b), these results
indicate that reduced association of RNF219 with the CCR4-NOT
complex upon pharmacological HDAC inhibition contributes to
acetylation-induced mRNA turnover.
Since accelerated mRNA turnover upon HDAC inhibition
involves direct acetylation of the exoribonuclease CAF1a53, we
finally wanted to know whether RNF219-mediated inhibition of
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Fig. 6 The SLiM is essential for the inhibitory function of RNF219. a Schematic illustration of the domain architecture of RNF219; RNF219-C (residues
434-726), RNF219 434-600, RNF219 434-600 ΔSLiM and RNF219 434-600 SLiM-3E are shown below. Mutated amino acid residues in RNF219 434-600
SLiM-3E are highlighted in red. b Coomassie-stained polyacrylamide gel of in vitro pull-down assays with MBP-Strep alone or four recombinant RNF219
constructs fused to MBP and a StrepII (Strep) affinity tag after incubation with the NOT9 module. c In vitro deadenylation assay with 50 nM of a 7-mer-A20
RNA substrate, 50 nM CCR4-NOTMINI complex and 2250 nM of MBP-Strep or indicated MBP-RNF219 constructs. Reactions were stopped at the indicated
time points and analyzed by electrophoresis using a 20% denaturing polyacrylamide gel; M, RNA size marker; C, RNA alone control. d Quantification of the
change in poly(A) tail length by plotting the most abundant tail length at each time point. Linear regression was used to determine the apparent
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test this, we co-expressed 3xFS-RNF219-RINGmut together with
CAF1a-K4A (Supplementary Fig. 15a), a hypoactive CAF1a
mutant with reduced levels of acetylation53, and measured
Roquin-induced degradation of a constitutive decay element
(CDE)2-containing β-globin reporter mRNA. The analysis
revealed that expression of 3xFS-RNF219-RINGmut slows down
reporter mRNA decay in the presence of CAF1a-WT (Supple-
mentary Fig. 15b–d; half-life of 9.9 ± 2.3 vs. 15.7 ± 3.0 h).
Importantly, 3xFS-RNF219-RINGmut also slows down reporter
mRNA decay in the presence of CAF1a-K4A (half-life of >24 vs.
>50 h), indicating that RNF219-mediated inhibition of mRNA
deadenylation and decay is independent of CAF1a acetylation.
In conclusion, our mRNA decay analyses provide compelling
evidence that RNF219 functions as an inhibitor of global mRNA
turnover, whose reduced expression upon HDAC inhibition
contributes to acetylation-induced mRNA turnover indepen-
dently of CAF1a acetylation.
Discussion
The CCR4-NOT complex is a key regulator of post-
transcriptional gene expression, responsible for both bulk and
transcript-specific deadenylation of mRNAs during co- and post-
transcriptional mRNA decay76–78. To fulfill these tasks, the
CCR4-NOT complex is embedded within a protein interaction
network comprising a multitude of mRNA decay-promoting
RBPs that provide target specificity3,51,79. In addition, the CCR4-
NOT complex is connected to general activators of deadenylation
such as proteins of the BTG/TOB family, which recruit mRNAs
by associating with the cytoplasmic poly(A)-binding protein
PABPC11,50,54,80. In contrast, less is known about regulatory
factors that directly modulate the activity of the CCR4-NOT
deadenylase. The DEAD-box helicase DDX6, which serves as an
activator for mRNA decapping and is important for miRNA-
mediated silencing of mRNAs, directly binds to NOT132,33,81 and
was recently found to enhance the deadenylating activity of
CAF182. The same study showed that another DEAD-box heli-
case, eIF4A2, also binds to NOT1, but inhibits CAF1-mediated
deadenylation and maintains long poly(A) tails on
bound mRNAs.
During the course of our study, two laboratories provided
independent evidence that RNF219 associates with the human
CCR4-NOT complex and negatively regulates deadenylation.
Guénolé et al. (2019) showed that tethering of RNF219 to a
reporter mRNA represses its translation and causes elongation of
the poly(A) tail. Du et al. (2020) showed that overexpression of
RNF219 reduces the deadenylation rate of reporter mRNAs
containing a miRNA-binding site or an m6A target site and
identified a role for RNF219 in controlling gene expression during
neuronal differentiation. Moreover, RNF219 was identified as a
binding partner of the CCR4-NOT complex when using the
CAF1-interacting protein TOB2 as a bait54. Our work presented
here establishes RNF219 as an acetylation-regulated cofactor of
the CCR4-NOT deadenylase complex (Fig. 1). We demonstrate
that RNF219 directly and stably binds to the complex via the
NOT9 module, and this interaction depends on a conserved SLiM
within the C-terminal low-complexity region of RNF219 (Figs. 2
and 6 and Supplementary Fig. 12c). Moreover, our in vitro
deadenylation assays provide firm evidence that RNF219 is an
antagonist of a reconstituted six-subunit human CCR4-NOT
complex comprising the scaffold subunit NOT1, the NOT6/
NOT7 catalytic module, the central NOT9 module and the
C-terminal NOT module (Fig. 4). Structure prediction of the
RNF219 SLiM revealed that it adopts the fold of an amphipathic
α-helix, which engages the concave and positively charged surface
of NOT9 (Fig. 5). Remarkably, structure-guided mutagenesis
confirmed that RNF219-mediated inhibition of deadenylation
depends on the direct interaction of RNF219 with NOT9, with
the crucial three hydrophobic amino acids located in the
C-terminal half of the SLiM (Fig. 6).
Using transcriptome-wide mRNA half-life measurements, our
study reveals for the first time that RNF219 indeed acts as an
inhibitor of global mRNA decay in cellulo (Fig. 7). Given that
both RNF219-WT and RNF219-RINGmut were able to rescue the
global defect in mRNA stability (Fig. 7c and Supplementary
Fig. 14a, b), RNF219 does not require its E3 ligase activity for
acting as an inhibitor of the CCR4-NOT deadenylase on bulk
mRNA. This agrees with the observation that RNF219-mediated
inhibition of deadenylation in vitro does not require the
N-terminal RING domain (Fig. 4). However, our results also
showed that the integrity of the RNF219 RING domain is needed
for stabilization of long-lived mRNAs in cells (Fig. 7d), indicating
that the E3 ligase activity may influence subgroups of mRNAs
beyond its role in destabilizing the RNF219 protein itself through
autoubiquitination (Fig. 3b).
Interestingly, the group of short-lived IEG mRNAs was stabi-
lized to a greater extent by RNF219-RINGmut than by RNF219-
WT (Fig. 7e). Not only does this show that the RING domain is
not required for stabilizing IEG mRNAs, but it further indicates
that the abundance of RNF219 is important for antagonizing the
degradation of these mRNAs. A possible scenario is that RNF219
competes for NOT9 binding with RBPs that serve as destabilizing
adaptors of IEG mRNAs.
Fig. 7 RNF219 attenuates global mRNA decay. a Western blot analysis of RNF219 expression in parental HeLa, RNF219 KO cells and RNF219 KO cells
stably expressing 3xFS-RNF219-WT or -RINGmut using antibodies as indicated. The relative RNF219 expression level is given below; tubulin serves as
loading control. b Scatter plot and marginal histograms depicting mRNA half-lives in RNF219 KO vs. parental HeLa cells. Transcriptome-wide mRNA
stability measurements were performed following transcription shut-off with 5 μg/ml actinomycin D (actD) and RNA-Seq analysis of rRNA-depleted total
RNA extracted at regular time intervals (n= 2). c Box-and-whisker plot depicting half-lives of all mRNAs determined in (b). The dotted line shows the
median mRNA half-life in parental HeLa cells; p values were calculated by two-sided, paired Wilcoxon rank sum test; parent. vs. KO p= 1.2 × 10−240;
parent. vs. WT p= 4.1 × 10−28; parent. vs. RINGmut p= 1.5 × 10−80; WT vs. RINGmut p= 0.008. d Box-and-whisker plot depicting half-lives of mRNAs
from (c) binned into discrete intervals as indicated. e Box-and-whisker plot depicting half-lives of IEG mRNAs as in (c); p values were calculated by two-
sided, paired Wilcoxon rank sum test; parent. vs. KO p= 1.3 × 10−10; parent. vs. WT p= 0.039; parent. vs. RINGmut p= 0.057; WT vs. RINGmut p= 0.011.
f Half-life measurement of IEG mRNAs KLF4, MYC and RHOB in parental HeLa cells and RNF219 KO cells stably expressing 3xFS-RNF219-RINGmut. Total
RNA was prepared as described in (b) and analyzed by qRT-PCR; values are presented as mean ± SD (n= 3; KLF4 p= 0.0139; MYC p= 0.037; RHOB
p= 0.0007). g Western blot analysis of RNF219 expression in RNF219 KO cells and RNF219 KO cells stably expressing 3xFS-RNF219-RINGmut following
treatment with 20 nM RMD for 16 h. h Half-life measurement of normally stable GAPDH and NCL mRNA in parental HeLa cells and RNF219 KO cells stably
expressing 3xFS-RNF219-RINGmut following treatment with 20 nM RMD for 16 h, as in (f). Values are presented as mean ± SD (n= 5; NCL p= 0.0405;
GAPDH p= 0.0543). p values in (f) and (h) were calculated by two-tailed, paired t test (*p < 0.05; ***p < 0.001). In all box-and-whisker plots the median is
indicated as center line, the interquartile range as box and the whiskers extend to the most extreme datapoint that is no >1.5 times the interquartile range
from the box. Source data for panels (a–c) and (e–h) are provided as a Source Data file.
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Downregulation of RNF219 expression by the HDAC inhibitor
RMD reduces its incorporation into the CCR4-NOT complex
(Fig. 1c–e, Supplementary Fig. 4), which is in good agreement
with our earlier discovery that pharmacological HDAC inhibition
leads to acceleration of poly(A) RNA degradation53. Indeed, we
could show that elevated expression of RNF219-RINGmut
antagonizes RMD-induced degradation of NCL and GAPDH
mRNAs (Fig. 7h). From these results we conclude that loss of
RNF219 expression contributes to the acetylation-induced
degradation of normally stable mRNAs. Since RNF219 acts
independently of CAF1 acetylation (Supplementary Fig. 15), its
dissociation from the complex synergizes with the stimulatory
effect that direct acetylation of CAF1 has on CCR4-NOT-
mediated mRNA degradation53.
Notably, our study revealed that RNF219 associates with the
CCR4-NOT complex through a direct interaction with the NOT9
module (Fig. 2c). NOT9/Caf40 is a highly conserved six
armadillo-repeat-containing protein83, which serves as docking
site for multiple CCR4-NOT-interacting RBPs such as TTP,
GW182/TNRC6, NOT4, Dm Bam and Dm Roquin32,33,37,39–41.
Our pull-down assays with recombinant proteins demonstrate
that RNF219 interacts exclusively with the NOT9 module
(Fig. 2c), unlike Dm Roquin, human NOT4 or human TTP, all of
which engage through additional interactions with other subunits
of the complex37,40,84. In line with our in vitro binding results,
partial KD of NOT9 was sufficient to abolish the co-precipitation
of RNF219 with the CCR4-NOT complex (Fig. 2b). Similar to Dm
Bam41 and Roquin40, the RNF219-NOT9 interaction depends on
a SLiM located in the C-terminal low-complexity region of
RNF219 (Figs. 2d and 6b)63. This peptide motif contains a short
stretch of highly conserved amino acids (Supplementary Fig. 12c)
and occupies the same NOT9 binding surface as the SLiMs of Dm
Bam41 and Roquin40 (Fig. 5a, Supplementary Fig. 12b). Hence,
the RNF219-NOT9 interaction represents a structurally con-
served mode of CCR4-NOT binding likely as a consequence of
convergent evolution.
In vitro experiments using reconstituted human CCR4-NOT
complexes have shown that NOT9, which is positioned proximal
to the exonuclease module, acts as an RNA-interaction surface
that has the potential to stimulate deadenylation through
improved substrate binding25. One possibility is that RNF219
inhibits deadenylation by masking the solvent-exposed RNA-
binding surface of NOT9, thereby displacing mRNAs non-
specifically (Fig. 8). This model would help to explain why labile
mRNAs, which rely on rapid and processive deadenylation, are
stabilized by RNF219 overexpression in this (Fig. 7e, f) and other
studies63,85. Since the rescue of long-lived mRNAs was found to
depend on the integrity of the RNF219 RING domain (Fig. 7d),
an alternative possibility is that RNF219 may directly affect CAF1
in a context-specific manner, given the proximity of NOT9 to the
catalytic module. Further experiments will be required to pre-
cisely determine how RNF219 attenuates CCR4-NOT dead-
enylase activity, and why the RING domain is required for
stabilizing long-lived, but not short-lived mRNAs.
Unlike yeast NOT4, which is an integral component of the
CCR4-NOT complex and fulfills versatile functions including
ubiquitin-mediated proteolysis, co-translational quality control
and proteasome assembly78,86, human and Dm NOT4 do not co-
purify with the CCR4-NOT complex (Fig. 1b)24,38. In contrast to
GW182/TNRC6 and TTP, which interact with tryptophan
binding pockets located on the convex surface of NOT932,33,39,
NOT4 utilizes a C-terminal SLiM, the so called Caf40-binding
motif, to associate with the concave surface of NOT937. Since
RNF219 also interacts with the concave surface of NOT9 via a
SLiM within its C-terminal low-complexity region (Figs. 2d, 5
and 6), NOT4 might compete with RNF219 for the same binding
site as it has been suggested for Dm Bam and Dm Roquin37. Since
RNF219 is tightly associated with the human CCR4-NOT com-
plex (Fig. 1b, Supplementary Fig. 3c), yet its RING domain is only
required for attenuating the degradation of long-lived transcripts
(Fig. 7d), it will be interesting to explore whether ubiquitination
associated with the mammalian CCR4-NOT complex might
regulate the stability of distinct mRNA subsets. Based on the
example of the RNA-binding E3 ligase MEX-3C, which was
found to facilitate the deadenylation of MHC-I mRNA by ubi-
quitination of CAF1a/NOT752, one is tempted to speculate that
the E3 ligase activity of RNF219 may control the deadenylation of
specific mRNAs beyond the RING domain-independent role of
RNF219 in attenuating global mRNA decay.
Methods
Cell culture. HeLa and HEK293 cells (a kind gift from Paul Anderson, Harvard
Medical School) were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% (v/v) fetal bovine serum (Sigma-Aldrich), 2 mM L-glu-
tamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin (all PAN Biotech) and
incubated at 37 °C in a 5% CO2 incubator. Cell lines were authenticated via SNP
profiling by Multiplexion GmbH at DKFZ. Cell lines were regularly tested for
mycoplasma contamination using a PCR Mycoplasma Test Kit (AppliChem).
Spodoptera frugiperda Sf21 insect cells (a kind gift from Imre Berger, University
of Bristol) were cultured in Sf900II medium (Thermo Fisher Scientific) and












































Fig. 8 Model of CCR4-NOT-mediated deadenylation and its inhibition by RNF219. The non-catalytic NOT2/3 and NOT9 modules facilitate access of
substrate poly(A) RNA to the catalytic NOT6/NOT7 module and thereby promote sequence-independent mRNA deadenylation. RNF219 interacts with the
NOT9 module via a SLiM (depicted as a helical peptide) within its C-terminal low-complexity region. RNF219 may occupy the RNA interaction surface on
NOT9 and hinder access of poly(A) RNA to the catalytic module. Alternatively, RNF219 may reduce the catalytic activity of CCR4 or CAF1, given the
proximity of the NOT9 and the catalytic module. Inhibition of CCR4-NOT-mediated deadenylation by RNF219 occurs in the absence of its N-terminal RING
domain and thus, is independent of its E3 ligase activity. The N-terminal RING domain of RNF219 is dispensable for stabilization of short-lived mRNAs yet
required for stabilization of long-lived mRNAs.
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Reverse siRNA transfection. Knock-down experiments were performed with
Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) and
reverse transfection. siRNAs were used at a final concentration of 100 nM and
diluted in Opti-MEM reduced serum medium (Thermo Fisher Scientific). For
NOT9 knock-down, cells were transfected with siRNA over a period of 48 h. For
NOT1 and HDAC1 knock-down, cells were transfected twice with siRNA over a
period of 72 h. siRNAs were designed with help of the siDESIGN Center (Horizon
Discovery) and synthesized by Eurofins Genomics. All siRNA sequences are listed
in Supplementary Data 4.
Plasmid transfection. HeLa cells were seeded in 10 cm dishes at a density of
1.5 – 1.8 × 106 cells/dish and transfected the following day with plasmid DNA
diluted in Opti-MEM reduced serum medium at a ratio of 1:3 using Lipofectamine
3000 transfection reagent (all Thermo Fisher Scientific). The medium was
exchanged 4 h post transfection. HEK293 cells were seeded in 15 cm dishes at a
density of 5 × 106 cells/dish and transfected as above.
CRISPR/Cas9-mediated genome editing. Target specific guide RNA sequences
were designed with help of CRISPR design tools (https://zlab.bio/guide-design-
resources) and are listed in Supplementary Data 4.
For tagging of endogenous NOT1, HeLa cells were transfected with an equal
amount of Cas9-guide RNA expressing constructs pSpCas9(BB)-2A-GFP-CNOT1-
guideC (p3568) and pSpCas9(BB)-2A-GFP-CNOT1-guideB (p3544) together with
the 3xFLAG-2xStrep(FST)-CNOT1 repair template containing mutated PAMs
(p3598) at a ratio of 4:1 using Lipofectamine 3000 transfection reagent (Thermo
Fisher Scientific). Cells were treated with 10 μM RS-1 (Sigma–Aldrich) for 24 h to
enhance CRISPR/Cas9-mediated genome editing efficiency. Two days after
transfection, GFP+ cells were enriched by FACS (FlowCore, Medical Faculty
Mannheim). Single clones were obtained by limiting dilution cloning using 96-well
plates and 10% (v/v) conditioned medium. Integration of the FST tag was
monitored in single clones by western blot analysis and sequencing of the
genomic locus.
To generate RNF219 KO cells, HeLa cells were transfected with an equal
amount of Cas9-guide RNA expressing constructs pSpCas9(BB)-2A-GFP-RNF219-
guideA (p3719) and pSpCas9(BB)-2A-GFP-RNF219-guideC (p3721) using
Lipofectamine 3000 transfection reagent and processed as described above.
Successful CRISPR/Cas9-mediated genome editing was monitored in single clones
by PCR and sequencing of the genomic locus.
NOT9 KO cells were generated by nucleofection of Alt-R CRISPR/Cas9
ribonucleoprotein complexes (Integrated DNA Technologies). Briefly, each crRNA
was resuspended at a concentration of 200 µM in 1x TE and mixed with 200 µM
tracrRNA (IDT) at an equimolar ratio. RNA hybridization was achieved by
incubation at 95 °C for 5 min, followed by stepwise cooling to room temperature.
CRISPR/Cas9 RNP complexes were prepared by gently mixing hybridized RNAs
with Cas9 protein (IDT) at a 1.2:1 molar ratio followed by 20 min incubation at
room temperature. For each nucleofection reaction, 1 × 106 Hela cells were washed
once in PBS and then resuspended in 90 µl supplemented solution R (Lonza)
followed by the addition of 4 µl electroporation enhancer (IDT) and 2.5 µl of each
prepared RNP complex. Nucleofection reactions were transferred into 100 µl
cuvettes (Lonza) and pulsed in an Amaxa 2b nucleofector using program A-28.
Following 48 h of incubation in conditioned medium, single clones were seeded
into 96-well plates as described above. Successful CRISPR/Cas9-mediated genome
editing was monitored in single clones by western blotting and sequencing of the
genomic locus.
Lentiviral transduction. To generate RNF219 KO cells stably expressing 3xFS-
RNF219-WT, -RINGmut or -ΔSLiM, lentiviral particles were produced in HEK293
cells by co-transfection of lentiviral expression vectors pWPI-3xFLAG-SBP-
RNF219-WT (p3761), -RINGmut (p3762) or -ΔSLiM (p3802) together with the
lentiviral packaging vector pCMV-Δ8.91 (p3785) and the VSV-G expression vector
pMD2.G (p3786) at a ratio of 3:3:1 with TurboFectin 8.0 (OriGene). Growth
medium was exchanged 6 h post transfection. After 2 days, virus-containing
supernatant was filtrated through a 0.45 μm syringe filter and used for two con-
secutive rounds of transduction using HeLa RNF219 KO clone #16 as target cell
line. Selection of stably transduced cells was performed with 6 μg/ml blasticidin S
(AppliChem) for 7–14 days after the second transduction.
Purification of the FST-tagged endogenous CCR4-NOT complex. 2.2 × 106
parental or FST-NOT1 (clone #47) HeLa cells were seeded in 15 cm dishes. 36 h
later, cells were washed once with ice-cold phosphate-buffered saline (PBS), har-
vested by scraping and flash-frozen in liquid nitrogen. For each condition,
10 × 15 cm dishes were used. Cells were mechanically disrupted using a Tissuelyzer
II (4 × 15 sec, 25 Hz) with 5 mm stainless steel beads (both from Qiagen). Cell
powder was solubilized in 9 ml ice-cold lysis buffer (20 mM Tris-HCl pH 7.5,
150 mM NaCl, 1.5 mM MgCl2, 1 mM DTT, 0.05% [v/v] NP-40) supplemented with
cOmplete EDTA-free Protease Inhibitor Cocktail (Roche). Lysates were vortexed
briefly and incubated on a rotating shaker for 10 min at 4 °C. Lysates were then
homogenized with 5 up and down strokes through a 27-gauge needle and cleared
by centrifugation at 13,000 g for 20 min at 4 °C. 200 µl equilibrated anti-FLAG M2
magnetic beads (Sigma–Aldrich) were then added for 3 h at 4 °C on a rotating
shaker, and beads were subsequently washed once with ice-cold lysis buffer and six
times with ice-cold wash buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 2.5 mM
MgCl2, 1 mM DTT, 0.1% [v/v] NP-40). Bound proteins were eluted in 100 µl lysis
buffer supplemented with 250 μg/ml 3xFLAG peptide (Sigma–Aldrich) for 1 h at
4 °C with vigorous shaking.
Quantitative mass spectrometry of the CCR4-NOT complex. FST-NOT1 (clone
#47) HeLa cells were subjected to SILAC by differential labeling using the SILAC
DMEM Lysine(8) Arginine(10) Kit (Silantes) and treated with 20 nM Romidepsin
(Abcam) or an equal volume of solvent (DMSO) for 16 h. Cells were washed once
with ice-cold PBS, harvested by scraping in ice-cold PBS supplemented with
HDAC inhibitors (1 μM Trichostatin A [Cell Signaling Technology], 10 mM
nicotinamide, 5 mM sodium butyrate [both from Sigma–Aldrich]), and subse-
quently flash-frozen in liquid nitrogen. Cell lysates were prepared as described
above. 25–30 mg of total protein from each SILAC label were combined prior to
affinity purification of FST-NOT1 with equilibrated anti-FLAG M2 magnetic beads
as described above. Eluted proteins were mixed with 5x SDS sample buffer
(250 mM HEPES pH 7.4, 10% [w/v] SDS, 50% [v/v] glycerol, 500 mM DTT,
bromophenol blue) and incubated for 10 min at 95 °C. Purified CCR4-NOT
complexes were shortly run into a 10% NuPAGE polyacrylamide Bis-Tris gel using
NuPAGE MOPS SDS Running Buffer (both from Thermo Fisher Scientific) and
stained with colloidal Coomassie (VWR). The gel was subjected to MS analysis at
the ZMBH Mass Spectrometry and Proteomics Core Facility. The Coomassie-
stained bands were cut out and processed as described with minor modifications87.
In brief, trypsin digestion was done overnight at 37 °C. The reaction was quenched
by addition of 20 µL of 0.1% trifluoroacetic acid (TFA; Biosolve, Valkenswaard, The
Netherlands) and the supernatant was dried in a vacuum concentrator before LC-
MS analysis. Nanoflow LC-MS2 analysis was performed with an Ultimate 3000
liquid chromatography system coupled to an QExactive HF mass spectrometer
(Thermo Fisher Scientific). Samples were dissolved in 0.1% TFA, injected to a self-
packed analytical column (75 µm x 200 mm; ReproSil Pur 120 C18-AQ; Dr Maisch
GmbH) and eluted with a flow rate of 300 nl/min in an acetonitrile-gradient
(3–40% [v/v]). The mass spectrometer was operated in data-dependent acquisition
mode, automatically switching between MS and MS2. Collision induced dissocia-
tion MS2 spectra were generated for up to 20 precursors with normalized collision
energy of 29%. Raw files were processed using MaxQuant v1.6.12.088 for peptide
identification and quantification. MS2 spectra were searched against the Uniprot
human proteome database (UP000005640_9606.fasta downloaded Nov 2019) and
the contaminants database provided together with the MaxQuant software using
the Andromeda search engine with the following parameters: Carbamidomethy-
lation of cysteine residues as fixed modification and acetyl (protein N-term), oxi-
dation (M) and deamidation (Q, N) as variable modifications, trypsin/P as the
proteolytic enzyme with up to 2 missed cleavages was allowed. The maximum false
discovery rate for proteins and peptides was 0.01 and a minimum peptide length of
7 amino acids was required. All other parameters were default parameters of
MaxQuant.
Analysis of mass spectrometry data. Downstream data analysis was performed
using LFQ values in Perseus v1.6.2.189. Commonly occurring contaminants, pro-
teins only identified by a modification site or those matching the reversed part of
the decoy database were excluded. To exclude proteins identified with low con-
fidence, proteins were filtered for LFQ values being present in at least 3 samples
across four biological repeat experiments. Means of log2-transformed LFQ values
were calculated and core CCR4-NOT subunits as well as candidate interactors were
revealed based on their exclusive identification in FST-NOT1 HeLa cells. SILAC
ratios were used to identify acetylation-regulated interactors of the CCR4-NOT
complex.
Glycerol gradient fractionation. HeLa cells were harvested and mechanically
lysed as described above. Cell powder was solubilized in ice-cold lysis buffer
(10 mM Tris-HCl pH 7.5, 10 mM NaCl, 10 mM MgCl2, 0.1% [v/v] Igepal CA-630)
supplemented with cOmplete EDTA-free Protease Inhibitor Cocktail (Roche).
Lysates were vortexed briefly and incubated on a rotating shaker for 10 min at 4 °C.
Lysates were then homogenized with 5 up and down strokes through a 27-gauge
needle and cleared by centrifugation at 100,000 g for 1 h at 4 °C. 3–4 mg total
protein was loaded onto linear gradients of 10–30% [w/v] glycerol dissolved in
20 mM Tris-HCl pH 8.0, 200 mMK(OAc), 5 mM Mg(OAc)2, 1 mM DTT sup-
plemented with cOmplete EDTA-free Protease Inhibitor Cocktail. Samples were
centrifuged at 229,900 g for 18 h at 4 °C using a swinging bucket rotor (Hitachi).
Fractions were eluted from the top of the gradient using a density gradient frac-
tionation system (Brandel). During elution, fractions of ~900 μl were collected.
Fractions were then supplemented with 300 μl 20 mM Tris-HCl pH 7.5 and 15 μl
StrataClean Resin (Agilent) and incubated overnight on a rotating shaker at 4 °C.
Proteins were eluted from the resin with 2x SDS sample buffer (100 mM HEPES
pH 7.4, 4% [w/v] SDS, 20% [v/v] glycerol, 200 mM DTT, bromophenol blue).
Co-immunoprecipitation. Cells were harvested by scraping in ice-cold PBS, cen-
trifuged at 400 g for 3 min at 4 °C and immediately flash-frozen in liquid nitrogen.
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Following cryogenic lysis with a Tissuelyzer II (4 × 15 sec, 25 Hz), cell powder was
solubilized in co-IP lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1.5 mM
MgCl2, 1 mM DTT, 0.05% [v/v] NP-40) supplemented with cOmplete EDTA-free
Protease Inhibitor Cocktail (Roche) and vortexed. Following incubation on a
rotating shaker for 10 min at 4 °C, lysates were cleared by centrifugation at 425 g for
5 min at 4 °C. 1% of total lysate was saved as input. Equal amounts of total protein
were used for IP using anti-FLAG M2 magnetic beads (Sigma–Aldrich), Dynabeads
MyOne Streptavidin C1 or anti-HA magnetic beads (both Thermo Fisher Scien-
tific) for 3 h at 4 °C on a rotating shaker. Beads were washed once with ice-cold
lysis buffer and six times with ice-cold wash buffer (20 mM Tris-HCl pH 7.5,
150 mM NaCl, 2.5 mM MgCl2, 1 mM DTT, 0.1% [v/v] NP-40). Bound proteins
were eluted with 2x SDS sample buffer.
Purification of 3xFS-RNF219 from HEK293 cells. HEK293 cells were seeded in
15 cm dishes at a density of 5 × 106 cells/dish and transfected the following day
with 5 μg of plasmid DNA diluted in Opti-MEM reduced serum medium at a ratio
of 1:3 using Lipofectamine 3000 transfection reagent (all Thermo Fisher Scientific).
The medium was changed 4 h post transfection. Cells were harvested and lysed in
co-IP lysis buffer as described above. The lysis buffer was additionally supple-
mented with 100 μM ZnCl2. RNF219 was immunoprecipitated with anti-FLAG M2
magnetic beads (Sigma–Aldrich) for 2–3 h at 4 °C. Beads were washed once with
ice-cold-lysis buffer and six times with wash buffer (20 mM Tris-HCl pH 7.5,
300 mM NaCl, 2.5 mM MgCl2, 1 mM DTT, 0.2% [v/v] NP-40, 20 μM ZnCl2).
RNF219 was eluted with 250 μg/ml 3xFLAG peptide (Sigma–Aldrich) in in vitro
ubiquitination buffer (30 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM DTT, 5 mM
MgCl2) for 1 h at 4 °C with vigorous shaking.
Purification of 3xFS-RNF219 from NOT9 KO cells. 2.5 × 106 CRISPR control
(clone #4) or NOT9 KO (clone #5) HeLa cells stably expressing 3xFS-RNF219 were
seeded in 15 cm dishes. 36 h later, cells were washed once with ice-cold PBS,
harvested by scraping and flash-frozen in liquid nitrogen. Cells were harvested and
lysed in co-IP lysis buffer as described above. Equal amounts of total protein were
used for the purification of 3xFS-RNF219 using anti-FLAG M2 magnetic beads
(Sigma–Aldrich) for 3 h at 4 °C on a rotating shaker. Beads were washed once with
ice-cold-lysis buffer and six times with wash buffer (20 mM Tris-HCl pH 7.5,
150 mM NaCl, 2.5 mM MgCl2, 1 mM DTT, 0.2% [v/v] NP-40). RNF219 was eluted
with 250 μg/ml 3xFLAG peptide (Sigma–Aldrich) in in vitro ubiquitination buffer
as described above.
Western blot analysis. For protein separation, 5–20% polyacrylamide gradient
Tris-glycine gels were made using standard protocols. The samples to be analyzed
were mixed with an appropriate volume of 5x or 2x SDS Laemmli buffer and
denatured for 10 min at 95 °C. 15–30 μg of total protein was loaded per sample and
electrophoresis was performed in Tris-glycine SDS running buffer (25 mM Tris,
250 mM glycine, 0.1% [w/v] SDS) at 30 mA/gel. Proteins were transferred onto
0.2 µm pore-sized nitrocellulose membranes (Peqlab) in Tris-glycine blotting buffer
(20 mM Tris, 150 mM glycine, 20% EtOH) at 90 V for 3 h at 4 °C by using a wet
blotting device. Loading and blotting efficiency were monitored by Ponceau S
staining of membranes. Following de-staining with TBS-T (50 mM Tris-HCl pH
7.5, 150 mM NaCl, 0.1% [v/v] Tween-20), membranes were blocked with 5% [w/v]
milk/PBS/0.01% [w/v] sodium azide for 1 h at room temperature on a shaking
platform. Membranes were incubated with primary antibodies diluted in PBS/
0.01% [w/v] sodium azide overnight at 4 °C on a shaking platform. The following
primary antibodies were used: mouse monoclonal anti-FLAG M2 (1:1000,
Sigma–Aldrich), rabbit polyclonal anti-histone H3 acetyl K27 (1:1000, Abcam),
rabbit polyclonal anti-NOT10 (1:1000, Proteintech), rabbit monoclonal anti-NOT7
(1:1000, Cell Signaling), rabbit polyclonal anti-acetylated lysine (1:1000, Cell Sig-
naling), rabbit polyclonal anti-RNF219 (1:500, Bethyl), rabbit polyclonal anti-FHL2
(1:1000, Abcam), rabbit polyclonal anti-TNKS1BP1 (1:1000, Bethyl), rabbit
monoclonal anti-NOT2 (1:1000, Cell Signaling), rabbit polyclonal anti-NOT9
(1:1000, Proteintech), mouse monoclonal anti-SBP (1:1000, Santa Cruz), rat
monoclonal anti-tubulin (1:1000, Abcam), rabbit monoclonal anti-NOT6 (1:1000,
Cell Signaling), rabbit polyclonal anti-histone H3 (1:1000, Abcam), rabbit poly-
clonal anti-NOT1 (1:1000, Proteintech), rabbit polyclonal anti-CAF1a (1:1000,
kindly provided by Ann-Bin Shyu, McGovern Medical School, University of Texas,
Houston), rabbit monoclonal anti-NOT3 (1:1000, Cell Signaling), mouse mono-
clonal anti-ubiquitin (1:1000, Cell Signaling), rabbit monoclonal anti-CAPZA1
(1:1000, Abcam), rabbit monoclonal anti-CAPZB (1:1000, Abcam), rabbit poly-
clonal anti-GFP (1:1000, Abcam), mouse monoclonal anti-HDAC1 (1:1000, Santa
Cruz). Membranes were washed 5–6 times over a time period of 1 h with TBS-T
before incubation with horseradish peroxidase (HRP)-coupled secondary anti-
bodies (1:10,000, donkey anti-rabbit, donkey anti-mouse, donkey anti-rat, all
Jackson ImmunoResearch) in PBS for 1 h at room temperature on a shaking
platform. After 5–6 washes with TBS-T over a time period of 1 h, membranes were
incubated with Western Lightning Plus-ECL (Perkin Elmer) or Clarity / Clarity
Max ECL Substrate (Bio-Rad) for 1 min, wrapped in foil and developed using X-ray
films or with a Fusion FX chemiluminescence detector in conjunction with
Evolution-Capt V18 software (Vilber).
Production and purification of MBP-RNF219-C. An MBP-tagged C-terminal
fragment of RNF219 (residues 434-726) was produced in Spodoptera frugiperda
Sf21 insect cells using the MultiBac baculovirus expression system as previously
described25. In brief, the Sf21cells were grown to a density of 2 × 106 cells/ml at
27 °C in Sf900II medium (Thermo Fisher Scientific), infected with the V1 RNF219-
C stock of baculovirus, and harvested 48 h after they stopped dividing. Cells were
resuspended in lysis buffer (50 mM HEPES, 500 mM NaCl, pH 7.5) and lysed using
a Branson Ultrasonics Sonifier SFX550. The lysate was cleared by centrifugation at
40,000 g for 1 h at 4 °C and filtered through 0.45 µm syringe-driven filters (Milli-
pore). The cleared and filtered lysate was diluted to 250 mM NaCl before it was
loaded onto a 5 ml MBPTrap column (Cytiva). The bound protein was eluted in
one step with binding buffer (50 mM HEPES, 200 mM NaCl, pH 7.5) supple-
mented with 30 mM maltose.
Production and purification of MBP-RNF219 434-600, 434-600 ΔSLiM and
434-600 SLiM-3E. An MBP-tagged minimal C-terminal fragment of RNF219
(residues 434-600) was produced in E. coli BL21 (DE3) Star cells (Thermo Fisher
Scientific) in LB medium at 20 °C as fusion protein carrying an N-terminal His6-
MBP tag and a C-terminal StrepII tag. Cells were resuspended in lysis buffer
(50 mM HEPES, 500 mM NaCl, 30 mM Imidazole, pH 7.5) and lysed using a
Branson Ultrasonics Sonifier SFX550. The lysate was cleared by centrifugation at
40,000 g for 1 h at 4 °C. The cleared lysate was loaded onto a 5 ml HisTrap column
(Cytiva). The bound protein was eluted over a linear gradient with elution buffer
(50 mM HEPES, 200 mM NaCl, 500 mM Imidazole, pH 7.5). The protein was then
diluted to 75 mM NaCl and loaded onto a 5 ml HiTrap Q (Cytiva) column to be
purified with anion exchange chromatography. In addition, the two mutated
constructs, RNF219 ΔSLiM (residues 434-600 with deletion of 540-549) and
RNF219 SLiM-3E (residues 434-600 with three mutations: L541E, M544E, M545E)
were produced and purified as the wild-type version.
StrepTactin pull-down assay. StrepII-tagged MBP, MBP-tagged RNF219-C
(residues 434-726), MBP-tagged RNF219 434-600, MBP-tagged RNF219 434-600
ΔSLiM and MBP-tagged RNF219 434-600 SLiM-3E were produced in E. coli BL21
(DE3) Star cells (Thermo Fisher Scientific) grown in auto-induction medium
overnight at 37 °C. Cells were lysed using a Branson Ultrasonics Sonifier SFX550 in
a buffer containing 50 mM Tris-HCl, 100 mM KCl, pH 8.5. The cleared lysates
were incubated with 50 µl of StrepTactin Sepharose High Performance resin
(Cytiva). After 1 h incubation, beads were washed four times with PBS containing
0.03% (v/v) Tween-20 and resuspended in binding buffer (50 mM Tris-HCl,
100 mM KCl, pH 8.5). Purified modules of the human CCR4-NOT complex
(40 µg) as previously described25,90 were added to the bead-bound proteins. After
1 h incubation, beads were washed three times with binding buffer and proteins
were eluted with 5 mM biotin in binding buffer. The eluted proteins were analyzed
by SDS polyacrylamide gel electrophoresis followed by Coomassie blue staining.
In vitro ubiquitination assay. Purification of human UBA1 (E1), UbcH5b,
UbcH5c, UbcH10, Cdc34 (E2s) and His-ubiquitin were previously described91–93.
Immuno-purified 3xFS-RNF219 or CCR4-NOT complex was incubated with
75 μM ubiquitin, 0.17 μM E1 enzyme and 1 μM E2 enzyme in in vitro ubiquiti-
nation buffer (30 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM DTT, 5 mM MgCl2)
supplemented with 5 mM ATP or an equal amount of solvent for 2 h at 32 °C. The
reaction was stopped by addition of 2x SDS sample buffer.
In vitro deadenylation assay. Deadenylation assays were performed under similar
conditions as previously described25,45,68. In brief, MBP alone, MBP-tagged Dm
Bam CBM, MBP-tagged RNF219-C, MBP-tagged RNF219 434-600, MBP-tagged
RNF219 434-600 ΔSLiM and MBP-tagged RNF219 434-600 SLiM-3E (all at
2250 nM) were incubated with CCR4-NOTMINI (50 nM) or NOT6:NOT7 (250 nM)
for 15 min at 4 °C before mixing with a 5′-fluorescein-labeled UCUAAAU(A)20
substrate RNA (50 nM). The deadenylation assay was carried out at 37 °C in a
buffer containing 20 mM PIPES pH 6.8, 10 mM KCl, 40 mM NaCl, and 2 mM
Mg(OAc)2 and stopped at regular time intervals by mixing with 3x reaction volume
of RNA loading dye (95% [v/v] deionized formamide, 17.5 mM EDTA pH 8, 0.01%
[w/v] bromophenol blue). The reaction products were resolved on a denaturing
TBE-urea polyacrylamide gel and imaged using an Amersham Typhoon Biomo-
lecular Imager (Cytiva). Densitometric quantitation of in vitro deadenylation
experiments was performed using ImageQuant TL software v8.2 (Cytiva). Dead-
enylation rates were estimated by the slope of the linear regression of the most
abundant tail length at each time point68.
Electrophoretic mobility shift assay (EMSA). Binding reactions contained
50 nM of labeled RNA and increasing concentrations of RNF219-C in a total
reaction volume of 15 µl of binding buffer (20 mM PIPES pH 6.8, 40 mM NaCl,
10 mM KCl, 2 mM Mg(OAc)2, 3% [w/v] Ficoll 400, 0.05% [v/v] NP-40, 0.03% [w/
v] Orange G). The proteins were incubated for 20 min with RNA at 37 °C. The
RNA-protein complexes were analyzed by electrophoresis on two gel types: 6%
nondenaturing polyacrylamide gel at 10 V/cm and 2% TBE/agarose gel at 10 V/cm.
Gels were imaged using an Amersham Typhoon Biomolecular Imager (Cytiva).
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Structure prediction using AlphaFold2. We performed NOT9:RNF219 complex
structure prediction using AlphaFold269 as implemented in ColabFold70. A
sequence where NOT9, residues 19-285, was concatenated at the C-terminal end to
RNF219, residues 424-726, via a 30-glycine linker was used as input in default
settings to generate five models. No additional templates or constraints were
employed.
mRNA decay assay. HeLa cells were washed once with pre-warmed PBS and
trypsinized. Cells were then resuspended in regular growth medium containing
5 μg/ml actinomycin D (AppliChem), and harvested at three (0, 3, 6 h) or four
consecutive time points (0, 2, 4, 6 h). Culture medium was aspirated, and cells were
immediately flash frozen in liquid nitrogen. RNA isolation was performed using
the Universal RNA Purification Kit (EURx/Roboklon) including an on-column
DNase digestion step. The RNA was analyzed by northern blotting, qRT-PCR or
RNA-Seq as described below. mRNA half-lives were calculated assuming first-
order decay kinetics. mRNA abundance was normalized to 18S rRNA and plotted
against time. Curves with the following equation were fitted to the data points by
linear regression: y= a × e(b × t), where y stands for the relative mRNA signal and t
for the time. mRNA half-lives were calculated as follows: t1/2= ln(2) / -b.
RNA-Seq. Prior to rRNA depletion using the Ribo-Zero Plus rRNA Depletion Kit
(Illumina), 1 µg total RNA was mixed with 2 µl of 1:100 diluted ERCC RNA Spike-
In Mix (Thermo Fisher Scientific). Libraries were prepared with the NEBNext Ultra
II Directional RNA Library Kit (NEB). Samples were equimolarly pooled and
sequenced on a NextSeq550 system equipped with NextSeq System Suite v2.2.0
(Illumina) with 75 bases single end.
Reads were mapped with STAR v2.5.3a94 to a common reference of the human
genome (hg38) and the ERCC RNA Spike-In Mix, providing the basic set of
Gencode V27 as downloaded from the UCSC Genome Browser
wgEncodeGencodeBasic27 table as transcript annotations, allowing up to 2
mismatches and chimeric read detection with a minimum of 10 nt per segment
(–chimSegmentMin 10). Read counts were summarized at the gene level with the
featureCounts function of the subread package v1.6.395. A read was only counted
when it was contained entirely within an exon. In order to calculate half-lives with
an in-house-developed R script, read counts were divided by the sum of all reads
assigned to the spike-in sequences. Linear regression was performed on log-
transformed read counts. Half-lives were calculated from the slope of the regression
line with the equation: ln(2) / -slope. Only genes with a positive half-life and a
coefficient of determination R2 > 0.5 in all conditions were used for subsequent
analyses. For categorization, mRNAs that are transcribed from immediate early
genes75, or are bound by YTHDF272, TTP/ZFP3673 or Roquin/RC3H174 were
grouped.
RNA gel electrophoresis and northern blotting. 3–10 µg total RNA was mixed
with 2x MOPS loading buffer (40 mM MOPS pH 7.0, 1 mM NaAc, 10 mM EDTA,
51.4% [v/v] formamide, 6.8% [v/v] formaldehyde, 7.1% [v/v] glycerol, 50 μg/ml
ethidium bromide, bromophenol blue) and denatured for 10 min at 65 °C. RNA
was resolved by size using 1.1% or 1.6% agarose/2% [v/v] formaldehyde/MOPS
(20 mM MOPS pH 7.0, 0.5 mM NaAc, 1 mM EDTA) gels. Loading and electro-
phoresis were examined under UV light and RNA was blotted over night with 8x
SSC buffer (1.2 M NaCl, 120 mM sodium citrate) onto Hybond-N+ nylon mem-
branes (GE Healthcare). RNA was immobilized on membranes by UV crosslinking
at 254 nm with 120 mJ/cm2 twice. Membranes were briefly rinsed in 2x SSC buffer
and transferred to hybridization glass tubes. Detection of poly(A) RNA, globin and
nucleolin mRNAs was performed as previously described2,53. For the detection of
poly(A) RNA, pre-hybridization was performed with 5 ml of hybridization buffer
(50% [v/v] formamide, 5x SSC, 0.1% [w/v] Ficoll 400, 0.1% [w/v] poly-
vinylpyrrolidone, 0.1% [w/v] BSA fraction V, 5 mM EDTA, 10 mM PIPES pH7.0,
0.4 mg/ml yeast RNA, 1% [w/v] SDS) for 30 min at 30 °C. For the detection of
globin and nucleolin mRNAs, pre-hybridization was performed with 10 ml of
hybridization buffer for 30 min at 55 °C. DIG-labeled oligo d(T)18, globin and
nucleolin probes (500 pmol) were denatured for 5 min at 95 °C and added to pre-
hybridized membranes. Hybridization was performed in a rotation oven over night
at 30 or 55 °C, respectively. For the detection of poly(A) RNA, membranes were
washed twice with pre-warmed 2x SSC/0.1% [w/v] SDS for 5 min at 30 °C and
twice with 0.1x SSC/0.1% [w/v] SDS for 15 min at room temperature. For the
detection of globin and nucleolin mRNAs, membranes were washed twice with pre-
warmed 2x SSC/0.1% [w/v] SDS for 5 min at 65 °C and twice with 0.5x SSC/0.1%
[w/v] SDS for 20 min at 65 °C. Membranes were briefly rinsed in DIG wash buffer
(10 mM maleic acid, 15 mM NaCl, 0.03% [v/v] Tween-20, pH 7.5) and blocked
with Northern Blot Blocking Solution (Roche) supplemented with Maleic Acid
buffer (10 mM maleic acid, 15 mM NaCl, pH 7.5) for 30 min at room temperature
on a shaking platform. Alkaline phosphatase-coupled α-DIG antibodies (Roche)
were added to the blocking solution at 1:5,000 and membranes were further
incubated for 30 min at room temperature prior to washing four times 15 min with
DIG wash buffer. For detection, membranes were briefly rinsed in DIG detection
buffer (130 mM Tris-HCl pH 9.5, 100 mM NaCl) and incubated for 5 min with
CDP-Star Nucleic Acid Chemiluminescence Reagent (Perkin Elmer) diluted 1:10 in
DIG detection buffer. Membranes were wrapped in foil and developed using X-ray
films or a Fusion FX chemiluminescence detector in conjunction with Evolution-
Capt V18 software (Vilber).
RT-qPCR. After on-column DNase digestion, 1 μg total RNA was reverse tran-
scribed with 100 U M-MLV Reverse Transcriptase (Promega) in the presence of
4 μM Random Hexamer Primer (Thermo Fisher Scientific), 20 U RNasin Ribo-
nuclease Inhibitor (Promega) and dNTPs (1 mM each) for 1 h at 37 °C. PCR
reactions were assembled in 384-well plates using a 5-fold diluted cDNA reaction,
400 nM of each gene-specific primer and the PowerUp SYBR Green Master Mix
(Thermo Fisher Scientific) in a final volume of 10 μl per well. Quantitative PCR was
performed on a QuantStudio 5 system (Thermo Fisher Scientific). Triplicates were
measured for every target/reference gene. To verify removal of genomic DNA and
to avoid genomic signals, all measurements included negative controls where the
reverse transcriptase was omitted from the cDNA reaction. To measure the effi-
ciency of individual primer pairs, dilution series of one cDNA sample were pre-
pared to generate a standard curve. Gene-specific primer sequences used for the
detection of mRNAs were designed with the Universal Probe Library Assay Design
Center (Roche), synthesized by Eurofins Genomics, and are listed in Supplemen-
tary Data 4.
Plasmid construction. The following plasmids have been previously described:
pcDNA3-HA (p2003)96, pTOPuro (p2433) and pTOPuro-mycStrep (p2484)47,
puroMXβ-CDE(O)37-V3 (p2823)2, pLNCX2-EGFP-Roquin (p2838)2,97, pcDNA3-
HA-PP7cp-CAF1a-WT (p2742) and pcDNA3-HA-PP7cp-CAF1a-K4A (p3241)53,
pnYC-vHM37,98 and pLIB99. pWPI-Blr (p3784), pCMV-Δ8.91 (p3785) and
pMD2.G (p3786) were kindly provided by Alessia Ruggieri (Center for Integrative
Infectious Disease Research, University Hospital Heidelberg). pMT2SM-HA-
CNOT9 (p2704) was kindly provided by Marc Timmers (Medical Center, Uni-
versity of Freiburg). pSpCas9(BB)-2A-GFP (p3511) was a gift from Feng Zhang
(Broad Institute, Massachusetts Institute of Technology, Addgene plasmid #48138).
AAVS1-Puro-PGK1-3xFLAG-2xStrep (p3513) was kindly provided by Yannick
Doyon (Center Hospitalier Universitaire de Québec Research Center-Université
Laval, Addgene plasmid #68375).
For TOPuro-CNOT1-gDNA (p3515), part of human CNOT1 flanking exon 2
was PCR amplified with primers G3983/G3984 from gDNA and inserted into
pcDNA4/TO (p2430, Thermo Fisher Scientific) via BamHI/XhoI.
The CNOT1 repair template was assembled as previously described100. To
generate the 3xFLAG-2xStrep-CNOT1-repair template (p3528), the left homology
arm was PCR amplified with primers G4090/G4091 from gDNA and inserted into
plasmid p3513 via NdeI/NcoI. The right homology arm was PCR amplified with
primers G4259/G4260 from plasmid p3515 and inserted via BstBI/EcoRI. To
generate the 3xFLAG-2xStrep-CNOT1-repair template containing mutated PAMs
(p3598), oligos G4502/G4503 were annealed and inserted into p3528 via EagI/
BamHI.
Scarless cloning of guide RNA sequence oligos was performed as previously
described101. For pSpCas9(BB)-2A-GFP-CNOT1-guideB (p3544) and pSpCas9(BB)-
2A-GFP-CNOT1-guideC (p3568), oligos G4086/G4087 (guide B) or G4384/G4385
(guide C) were annealed and inserted into plasmid p3511 via BbsI sites. To generate
pSpCas9(BB)-2A-GFP-RNF219-guideA (p3719) and pSpCas9(BB)-2A-GFP-RNF219-
guideC (p3721), oligos G5014/G5015 (guide A) or G5018/G5019 (guide C) were
annealed and inserted into plasmid p3511 via BbsI sites.
To generate pcDNA4/TO-3xFLAG-SBP-RNF219 (p3701), the 3xFLAG coding
sequence was PCR amplified with primers G3987/G3988 from plasmid p3513 and
ligated via NheI to the SBP coding sequence, which was amplified by PCR with
primers G3990/G3991 from plasmid p2484. The ligation product was subsequently
cloned into plasmid p2430 via HindIII/SacI, and the RNF219 coding sequence,
amplified by PCR with primers G4972/G4973 from cDNA, was cloned into
BamHI/XhoI of the resulting vector. pcDNA4/TO-3xFLAG-SBP-RNF219-
RINGmut (p3709) was generated by site-directed mutagenesis of plasmid p3701
with primers G4984/G4985. Likewise, pcDNA4/TO-3xFLAG-SBP-RNF219-ΔSLiM
(p3796) was generated by site-directed mutagenesis of plasmid p3701 with primers
G5335/G5336.
For pWPI-3xFLAG-SBP-Stop (p3760), the 3xFLAG-SBP coding sequence was
amplified by PCR with primers G5172/G5174 from plasmid p3701 and inserted
into plasmid p3784 via BamHI/SmaI. For pWPI-3xFLAG-SBP-RNF219-WT
(p3761), pWPI-3xFLAG-SBP-RNF219-RINGmut (p3762) and pWPI-3xFLAG-
SBP-RNF219-ΔSLiM (p3802), the RNF219 coding sequence was amplified by PCR
with primers G5172/G5173 from plasmid p3701 (RNF219-WT), plasmid p3709
(RNF219-RINGmut) and plasmid p3796 (RNF219-ΔSLiM), respectively, and
inserted into plasmid p3784 via BamHI/SmaI.
To generate pcDNA3-HA-NOT9 (p3798), the NOT9 coding sequence was
amplified by PCR with primers G5339/G5340 from plasmid p2704 and inserted
into plasmid p2003 via BamHI/XhoI.
To produce TOPuro-FLAG-TEV-SBP (p3373), a NheI restriction site was
introduced into p2433 via site-directed mutagenesis with primers G3483/G3484,
into which annealed primers G3485/G3486 introducing a FLAG-TEV site and a
PCR product coding for SBP, generated with primers G3487/G3488 from p2484 as
template, were consecutively inserted via XhoI/NheI and NheI/BclI, respectively.
To generate TOPuro-CAF1a-WT-FLAG-TEV-SBP (p3374) and TOPuro-CAF1a-
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K4A-FLAG-TEV-SBP (p3376), the coding sequence of CAF1a was excised from
p2742 and p3241 and inserted into p3373 via BamHI/XhoI.
To produce pnYC-vMH-RNF219-C, a synthetic gene fragment of human
RNF219 encoding residues 434-726 was codon optimized for expression in E. coli
(GeneWiz) and inserted into the pnYC-vHM plasmid via NdeI/BamHI.
To generate pLIB-vHM-RNF219-C, human RNF219 encoding residues 434-726
was PCR amplified with primers EV0625/EV0626 from a synthetic gene fragment
of RNF219 codon optimized for expression in S. frugiperda (GenScript) and,
together with a 6xHis-MBP tag, PCR amplified from plasmid pnYC-vHM with
primers EV0623/EV0624, simultaneously inserted into pLIB via Gibson assembly.
To produce pnYC-pHM-RNF219 434-600, human RNF219 encoding residues
434-600 was PCR amplified with primers JC01/JC02 using pnYC-vHM-RNF219-C
as template and inserted into pnYC-pHM (same as pnYC-vHM but with a 3 C
protease cleavage sequence instead of the TEV sequence) via Gibson assembly.
pnYC-pHM-RNF219 434-600 ΔSLIM and pnYC-pHM-RNF219 434-600
SLIM-3E were generated by site-directed mutagenesis of pnYC-pHM-RNF219 434-
600 using overlapping primers JC018/JC019 and JC020/JC021, respectively.
Mutations, cloning boundaries and coding sequences of all plasmids were
verified by Sanger sequencing (Eurofins Genomics). All DNA oligonucleotides used
for cloning are listed in Supplementary Data 4.
Statistics and reproducibility. Data are presented as mean ± SD, unless otherwise
stated. The number of independent experiments, the type of statistical test and
specific p values are indicated in the figure legends. p < 0.05 were considered sta-
tistically significant. All experiments were repeated independently two to six times
with similar results.
Blots and gels were processed and analyzed with ImageJ v1.52102. Sequence
alignments were generated with Clustal Omega. ChIP-Seq data were visualized
with Integrative Genomics Viewer v2.9.4. High throughput data were analyzed
with R v3.6.3. Statistical analysis was performed using Microsoft Excel 2019 or
GraphPad Prism v8.4.1. Statistical significance was calculated by performing a two-
sided, paired Student’s t test whenever an equal number of repeats was performed
for every condition. When values were calculated relative to a control treatment,
control samples were set to 1 and a two-sided, one sample t test was performed.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data supporting the findings of this study are available from the corresponding
authors upon reasonable request. Raw and analyzed data of RNA-Seq experiments have
been deposited at the GEO under the accession number GSE172019. Raw and processed
mass spectrometry data have been deposited at the ProteomeXchange Consortium via
the PRIDE partner repository with the dataset identifier PXD027237. ChIP-Seq data
from CD4+ T-cells61 were obtained from GEO under the accession number GSE15735.
Source data of experiments shown in Figs. 1b–e, 2b–e, 3b–e, 4b–f, 6b–d, 7a–c, 7e–h and
Supplementary Figs. 2a–e, 3a–c, 4a–b, d–f, 5, 6b, 10a, b, 11b, c, 13a, b, 14a–g, 15a–d are
provided with this paper. Source data are provided with this paper.
Code availability
The pipeline used to calculate mRNA half-lives from RNA-Seq data has been deposited
at the OSF (https://osf.io/vskje/?view_only=13961ac6d5cd4d3ba3521615cc38fe47).
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